CAMBRIDGE, Mass., May 14, 2026
Editas Medicine presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting demonstrating that its lead in vivo CRISPR gene editing candidate, EDIT-401, achieved durable LDL cholesterol (LDL-C) lowering of ≥90% following a single dose in non-human primates. The findings support continued development of EDIT-401 as a potential one-time treatment for hyperlipidemia and cardiovascular disease.
The company reported that LDL-C reduction remained durable through approximately six months across multiple dose groups ranging from 1.5 mg/kg to 3.0 mg/kg. Notably, the therapy achieved these results with only 10-40% functional editing of LDLR alleles and a greater than six-fold increase in hepatic LDLR protein expression, highlighting the efficiency of Editas’ proprietary in vivo gene upregulation strategy.
EDIT-401 Demonstrates Strong Safety and Liver Targeting
According to Editas Medicine, EDIT-401 demonstrated a promising preclinical safety profile with no adverse clinical findings observed at therapeutically relevant dose levels in non-human primates. Researchers also reported that the highest delivery of the therapy occurred in hepatocytes, the primary liver cells involved in cholesterol regulation, while delivery to non-target tissues remained low and oocyte exposure was undetectable.
Additional preclinical mouse studies evaluating pharmacokinetics and pharmacodynamics showed that dose adjustments may not be necessary for patients with Heterozygous Familial Hypercholesterolemia (HeFH), a common inherited disorder causing elevated LDL cholesterol levels. The company believes these findings further strengthen the translational potential of EDIT-401 for broad cardiovascular disease applications.
The therapy uses a CRISPR-based in vivo gene editing approach designed to increase LDL receptor (LDLR) protein levels, enabling more efficient removal of LDL cholesterol from circulation. Unlike traditional lipid-lowering therapies that require lifelong treatment, EDIT-401 is being developed as a potentially durable, one-time therapeutic intervention.
Advertisement
Gene Upregulation Strategy Expands Beyond Cardiovascular Disease
Beyond the EDIT-401 program, Editas also presented data supporting its broader in vivo gene upregulation platform, including research leveraging DNA large language prediction models (DNA-LLM) to accelerate development of gene editing strategies aimed at activating compensatory biological pathways.
Dr. Linda C. Burkly, Executive Vice President and Chief Scientific Officer at Editas Medicine, stated that the new data reinforce confidence in EDIT-401’s ability to deliver meaningful and durable LDL-C lowering while also validating the company’s differentiated upregulation platform across multiple disease areas.
The data were presented during both oral and poster sessions at ASGCT 2026, as well as at the TIDES USA 2026 Oligonucleotide and Peptide Therapeutics Conference, highlighting growing industry interest in precision in vivo gene editing approaches for cardiovascular and metabolic diseases.
Source: Editas Medicine press release
